Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Biotechnology & Applied Microbiology, Medicine, Research & Experimental, Research & Experimental Medicine, GENOME-WIDE ASSOCIATION, ANDROGEN-DEPRIVATION THERAPY, COMMON GENETIC-VARIANTS, DNA-REPAIR GENES, SUSCEPTIBILITY LOCI, RADICAL PROSTATECTOMY, SEQUENCE VARIANTS, ANTIGEN RECURRENCE, CLINICAL-OUTCOMES, BIOMARKER LEVELS, Decision Making, Humans, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Risk Factors, 06 Biological Sciences, 08 Information and Computing Sciences, 10 Technology

Abstract:

Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs, and mortality. Epidemiological studies have suggested an important role of genetics in PCa development. Because of this, an increasing number of single nucleotide polymorphisms (SNPs) had been suggested to be implicated in the development and progression of PCa. While individual SNPs are only moderately associated with PCa risk, in combination, they have a stronger, dose-dependent association, currently explaining 30% of PCa familial risk. This review aims to give a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. We will highlight the major research questions in the translation of SNP identification into clinical practice.